Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2026)
Crinetics Pharmaceuticals' quarterly Income from Continuing Operations came in at 127714000.0 in Q1 2026, down 32.25% year-on-year from 188504442.96 in Q1 2025, and down 4.14% quarter-over-quarter from 122635000.0 in Q4 2025.
Crinetics Pharmaceuticals has reported Income from Continuing Operations for 10 years, with the latest figure at 127714000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 32.25% year-over-year to 127714000.0; the trailing twelve-month figure through Mar 2026 stood at 496097000.0 (down 51.23% YoY), and the FY2025 full-year result was 465317000.0, down 56.18% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 127714000.0, down from 122635000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 33634000.0 in Q1 2022, with the low at 130091000.0 in Q3 2025.
- Average Income from Continuing Operations over 5 years is 74298764.71, with a median of 66209000.0 recorded in 2024.
- Year-over-year, Income from Continuing Operations declined 20.23% in 2023 and plunged 69.33% in 2025.
- Tracing CRNX's Income from Continuing Operations over 5 years: stood at 45652000.0 in 2022, then declined by 22.53% to 55936000.0 in 2023, then tumbled by 44.08% to 80595000.0 in 2024, then plunged by 52.16% to 122635000.0 in 2025, then retreated by 4.14% to 127714000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 127714000.0 (Q1 2026), 122635000.0 (Q4 2025), and 130091000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | -127.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -127.71 Mn |
| Dec 31, 2025 | -122.64 Mn |
| Sep 30, 2025 | -130.09 Mn |
| Jun 30, 2025 | -115.66 Mn |
| Mar 31, 2025 | -96.57 Mn |
| Dec 31, 2024 | -80.60 Mn |
| Sep 30, 2024 | -76.83 Mn |
| Jun 30, 2024 | -74.04 Mn |
| Mar 31, 2024 | -66.21 Mn |
| Dec 31, 2023 | -55.94 Mn |
| Sep 30, 2023 | -56.41 Mn |
| Jun 30, 2023 | -50.89 Mn |
| Mar 31, 2023 | -45.94 Mn |
| Dec 31, 2022 | -45.65 Mn |
| Sep 30, 2022 | -41.95 Mn |
| Jun 30, 2022 | -42.33 Mn |
| Mar 31, 2022 | -33.63 Mn |
| Dec 31, 2021 | -30.81 Mn |
| Sep 30, 2021 | -27.78 Mn |
| Jun 30, 2021 | -26.07 Mn |
| Mar 31, 2021 | -22.89 Mn |
| Dec 31, 2020 | -21.74 Mn |
| Sep 30, 2020 | -18.33 Mn |
| Jun 30, 2020 | -16.67 Mn |
| Mar 31, 2020 | -17.23 Mn |
| Dec 31, 2019 | -14.56 Mn |
| Sep 30, 2019 | -14.39 Mn |
| Jun 30, 2019 | -12.39 Mn |
| Mar 31, 2019 | -9.03 Mn |
| Dec 31, 2018 | -8.43 Mn |
| Sep 30, 2018 | -7.54 Mn |
| Jun 30, 2018 | -5.53 Mn |
| Mar 31, 2018 | -5.46 Mn |
| Dec 31, 2017 | -2.50 Mn |
| Sep 30, 2017 | -2.37 Mn |
| Jun 30, 2017 | -1.64 Mn |